Product Name: ADAMTS4 Antibody
Species Reactivity: Human, Mouse, Rat
Tested Applications: ELISA, IHC, WB
Applications: ADAMTS4 antibody can be used for detection of ADAMTS4 by ELISA at 1:62500. ADAMTS4 antibody can be used for detection of ADAMTS4 by western blot at 0.5 μg/mL, and HRP conjugated secondary antibody should be diluted 1:50,000 – 100,000.
User Note: Optimal dilutions for each application to be determined by the researcher.
Predicted Molecular Weight: 37 kDa, 90 kDa
Immunogen: Antibody produced in rabbits immunized with a synthetic peptide corresponding a region of human ADAMTS4.
Host Species: Rabbit
Purification: Antibody is purified by peptide affinity chromatography method.
Physical State: Lyophilized
CAS NO.: 1872382-47-2
Product: UNC3866
Buffer: Antibody is lyophilized in PBS buffer with 2% sucrose. Add 50 μL of distilled water. Final antibody concentration is 1 mg/mL.
Concentration: 1 mg/ml
Storage Conditions: For short periods of storage (days) store at 4˚C. For longer periods of storage, store ADAMTS4 antibody at -20˚C. As with any antibody avoid repeat freeze-thaw cycles.
Clonality: Polyclonal
Conjugate: Unconjugated
Alternate Names: ADAMTS4, ADAMTS-2, ADAMTS-4, ADMP-1, KIAA0688
Accession NO.: AAH30812
Protein Ino: 21410063
Official Symbol: ADAMTS4
Geneid: 9507
Background: ADAMTS4 is a member of the ADAMTS (a disintegrin and metalloproteinase with thrombospondin motifs) protein family. Members of the family share several distinct protein modules, including a propeptide region, a metalloproteinase domain, a disintegrin-like domain, and a thrombospondin type 1 (TS) motif. Individual members of this family differ in the number of C-terminal TS motifs, and some have unique C-terminal domains. ADAMTS4 lacks a C-terminal TS motif. It is responsible for the degradation of aggrecan, a major proteoglycan of cartilage, and brevican, a brain-specific extracellular matrix protein. The cleavage of aggrecan and brevican suggests key roles of this enzyme in arthritic disease and in the central nervous system, potentially, in the progression of glioma.
PubMed ID:http://aac.asm.org/content/52/4/1396.abstract
